STAA (STAAR Surgical Company) Stock Financials & Earnings

STAASTAAR Surgical Company

Mkt Cap$860M

Revenue (TTM)$239M

Net Income (TTM)-$80M

EPS (TTM)-$1.62

Free Cash Flow (TTM)-$34M

Gross Margin76.2%

Op. Margin-38.3%

Net Margin-33.6%

FCF Margin-14.4%

P/S Ratio (TTM)3.6x

P/E Ratio (TTM)—

YoY Rev Growth-23.7%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$74M	$58M	$3M
Q2 23	$92M	$71M	$9M
Q3 23	$80M	$64M	$6M
Q4 23	$76M	$61M	$10M
Q1 24	$77M	$61M	-$2M
Q2 24	$99M	$78M	$12M
Q3 24	$89M	$68M	$6M
Q4 24	$49M	$32M	-$28M
Q1 25	$43M	$28M	-$57M
Q2 25	$44M	$33M	-$30M
Q3 25	$95M	$78M	$18M
Q4 25	$58M	$44M	-$23M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 23	$10M	$18M	$26M
Q2 23	$12M	$18M	$32M
Q3 23	$11M	$19M	$27M
Q4 23	$11M	$17M	$23M
Q1 24	$13M	$23M	$27M
Q2 24	$12M	$24M	$31M
Q3 24	$14M	$22M	$27M
Q4 24	$12M	$21M	$26M
Q1 25	$14M	$24M	$25M
Q2 25	$10M	$21M	$26M
Q3 25	$9M	$21M	$23M
Q4 25	$10.2B	$20M	$28M

Revenue Segments

Quarter	Cataract Intraocular Lenses	Implantable Collamer Lenses	Other Surgical Products
Q1 23	$1M	$71M	$1M
Q2 23	$40K	$93M	—
Q3 23	$221K	$81M	—
Q4 23	—	$75M	$2M
Q1 24	—	$77M	$205K
Q2 24	—	$99M	—
Q3 24	—	$89M	—
Q1 25	—	$41M	$1M

Revenue by Geography

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$90M	$114M	$204M
Q2 23	$95M	$97M	$192M
Q3 23	$127M	$61M	$188M
Q4 23	$183M	$38M	$221M
Q1 24	$224M	$21M	$245M
Q2 24	$193M	$42M	$235M
Q3 24	$164M	$72M	$236M
Q4 24	$144M	$86M	$230M
Q1 25	$173M	$50M	$223M
Q2 25	$167M	$23M	$190M
Q3 25	$176M	$17M	$193M
Q4 25	$153M	$0	$153M

Shares Outstanding

Revenue Per Employee

Revenue / Employee